Up to two extra alemtuzumab courses may help mitigate clinical and MRI disease activity in RRMS patients with breakthrough disease activity after the initial two-course regimen, research suggests. While the drug was first approved to be given as two annual courses, a study involving 811 patients with RRMS found that giving additional third and possibly ...
Additional courses of alemtuzumab effective and safe in RRMS
By Michael Woodhead
4 Dec 2019